NKGen Biotech Presented Phase I Clinical Trial Data At The 16th Annual Clinical Trials On Alzheimer's Disease Conference
Portfolio Pulse from Benzinga Newsdesk
NKGen Biotech Inc. (NASDAQ:NKGN) presented Phase I trial data on its investigational NK cell therapy, SNK01, for Alzheimer's disease at the Clinical Trials on Alzheimer's Disease Annual Meeting. The data showed that 90% of patients demonstrated improvement or maintained stable cognitive function following 11 weeks of treatment. SNK01 appears to cross the blood-brain barrier to reduce Cerebrospinal Fluid Aβ42/40 and pTau181 levels and neuroinflammation. The company has received U.S. IND clearance for a Phase I/IIa study in patients with moderate stage Alzheimer's disease.
October 26, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NKGen Biotech's Phase I trial data for Alzheimer's treatment SNK01 shows promising results, potentially leading to increased investor interest.
The positive Phase I trial data for NKGen Biotech's Alzheimer's treatment SNK01 indicates potential for the drug's success in later trial phases. This could lead to increased investor interest and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100